Tango Therapeutics, Inc. (TNGX): Results of Operations and Financial Condition
Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da
How this was made
The 30-second read
Why it matters
The most tradable elements are the newly disclosed Phase 1/2 combination efficacy metrics, the stated regulatory dialogue toward a registrational plan, and the company’s cash runway and cost trajectory.
Market read
Traders can use the disclosed efficacy metrics, cash balance, and upcoming trial-design and conference milestones to adjust probability-weighted outcomes into the next catalysts.
What to watch
The filing also shows rising R&D and G&A costs and $0 collaboration revenue for the quarter, so burn and financing expectations still matter despite the $1.0B cash balance.
Tango Therapeutics reported second-quarter 2026 results, highlighted positive Phase 1/2 vopimetostat plus daraxonrasib data in pancreatic cancer, and is preparing a registrational path and Phase 3 trial design.
Clinical progress was the central positive, including a reported 92% objective response rate and 90% six-month progression-free survival rate for vopimetostat plus daraxonrasib in the stated patient population, while $1.0 billion of cash, cash equivalents and marketable securities supports the current operating plan. Financial results reflected the end of collaboration revenue and higher operating expenses and net loss.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended June 30GAAP | $ — | – | – |
| Research and development expenses, three months ended June 30GAAP | 37,199 | – | – |
| General and administrative expenses, three months ended June 30GAAP | 22,586 | – | – |
| Total operating expenses, three months ended June 30GAAP | 59,785 | – | – |
| Loss from operations, three months ended June 30GAAP | (59,785 ) | – | – |
| Other income, net, three months ended June 30GAAP | 4,445 | – | – |
| Loss before income taxes, three months ended June 30GAAP | (55,340 ) | – | – |
| Provision for income taxes, three months ended June 30GAAP | (1 ) | – | – |
| Net loss, three months ended June 30GAAP | $ (55,341 ) | – | – |
| Net loss per common share, basic and diluted, three months ended June 30GAAP | $ (0.37 ) | – | – |
| Weighted average number of common shares outstanding, basic and diluted, three months ended June 30GAAP | 149,875,939 | – | – |
| Collaboration revenue, six months ended June 30GAAP | $ — | – | – |
| Research and development expenses, six months ended June 30GAAP | 70,734 | – | – |
| General and administrative expenses, six months ended June 30GAAP | 37,821 | – | – |
| Total operating expenses, six months ended June 30GAAP | 108,555 | – | – |
| Loss from operations, six months ended June 30GAAP | (108,555 ) | – | – |
| Other income, net, six months ended June 30GAAP | 7,701 | – | – |
| Loss before income taxes, six months ended June 30GAAP | (100,854 ) | – | – |
| Provision for income taxes, six months ended June 30GAAP | (2 ) | – | – |
| Net loss, six months ended June 30GAAP | $ (100,856 ) | – | – |
| Net loss per common share, basic and diluted, six months ended June 30GAAP | $ (0.68 ) | – | – |
| Weighted average number of common shares outstanding, basic and diluted, six months ended June 30GAAP | 148,660,404 | – | – |
| Vopimetostat plus daraxonrasib objective response rate in MTAP-deleted, RAS-mutant pancreatic cancerother | 92% | – | – |
| Vopimetostat plus daraxonrasib six-month progression-free survival rate in MTAP-deleted, RAS-mutant pancreatic cancerother | 90% | – | – |
2H 2026 outlook
- NoteFinalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pancreatic cancer in 2H 2026
- NoteDisclose vopimetostat lung cancer monotherapy data in 2H 2026
- NoteRelease initial TNG456 data in glioblastoma and other cancers in 2H 2026
- NoteInitiate Phase 1/2 vopimetostat + ERAS-0015 (Erasca) combination study in 2H 2026
- NotePresent Phase 1/2 data of vopimetostat in combination with RAS(ON) inhibitors at the 2026 ESMO Congress in Madrid, Spain from October 23-27, 2026
- NoteThe Company expects its cash, cash equivalents and marketable securities to fund its current operating plan.
What drove it
- Vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival rate in MTAP-deleted, RAS-mutant pancreatic cancer, according to the Company.
- Research and development expense increased primarily due to increased spend related to advancement of the vopimetostat and TNG456 clinical programs.
- The research and development increase was partially offset by decreased spend resulting from portfolio prioritization efforts.
- General and administrative expense increased primarily due to personnel-related costs, including share-based compensation expense.
- All remaining deferred revenue under the Gilead collaboration was recognized during the year ended December 31, 2025 following truncation of the collaboration agreement and conclusion of all research activities.
Concerns
- Collaboration revenue was $ — for the three months ended June 30, 2026, versus $ 3,181 for the same period in 2025.
- Total operating expenses were 59,785 for the three months ended June 30, 2026, versus 44,148 for the same period in 2025.
- Net loss was $ (55,341 ) for the three months ended June 30, 2026, versus $ (38,853 ) for the same period in 2025.
- The Company remains dependent on clinical development, regulatory dialogue, third parties conducting trials and supplying drug substance and drug product, and the safety and efficacy of its product candidates.
What to watch
- Phase 1/2 vopimetostat combination data presentation at the 2026 ESMO Congress in Madrid, Spain from October 23-27, 2026.
- Finalization of the Phase 3 randomized-controlled trial design for the front-line pancreatic cancer combination approach in 2H 2026.
- Vopimetostat lung cancer monotherapy data in 2H 2026.
- Initial TNG456 data in glioblastoma and other cancers in 2H 2026.
- Initiation of the Phase 1/2 vopimetostat plus ERAS-0015 combination study in 2H 2026.
- Regulatory and collaborator discussions with Revolution Medicines regarding a registrational plan and path forward for vopimetostat plus daraxonrasib.
Balance sheet and cash flow
- Cash and cash equivalents: $ 345,558 as of June 30, 2026; $ 112,279 as of December 31, 2025. In thousands.
- Marketable securities: 668,432 as of June 30, 2026; 230,859 as of December 31, 2025. In thousands.
- Cash, cash equivalents and marketable securities: $1.0 billion as of June 30, 2026.
- Restricted cash: $ — as of June 30, 2026; $ 428 as of December 31, 2025. In thousands.
- Prepaid expenses and other current assets: 17,681 as of June 30, 2026; 10,190 as of December 31, 2025. In thousands.
- Total current assets: 1,031,671 as of June 30, 2026; 353,756 as of December 31, 2025. In thousands.
- Property and equipment, net: 6,094 as of June 30, 2026; 6,868 as of December 31, 2025. In thousands.
- Operating lease right-of-use assets: 33,664 as of June 30, 2026; 35,624 as of December 31, 2025. In thousands.
- Restricted cash, net of current portion: 2,139 as of June 30, 2026; 2,139 as of December 31, 2025. In thousands.
- Other assets: 312 as of June 30, 2026; 303 as of December 31, 2025. In thousands.
- Total assets: $ 1,073,880 as of June 30, 2026; $ 398,690 as of December 31, 2025. In thousands.
- Accounts payable: $ 1,810 as of June 30, 2026; $ 1,182 as of December 31, 2025. In thousands.
- Accrued expenses and other current liabilities: 15,546 as of June 30, 2026; 17,759 as of December 31, 2025. In thousands.
- Operating lease liabilities: 2,943 as of June 30, 2026; 2,738 as of December 31, 2025. In thousands.
- Total current liabilities: 20,299 as of June 30, 2026; 21,679 as of December 31, 2025. In thousands.
- Operating lease liabilities, net of current portion: 29,049 as of June 30, 2026; 30,832 as of December 31, 2025. In thousands.
- Total liabilities: 49,348 as of June 30, 2026; 52,511 as of December 31, 2025. In thousands.
- Total stockholders’ equity: 1,024,532 as of June 30, 2026; 346,179 as of December 31, 2025. In thousands.
- Total liabilities and stockholders’ equity: $ 1,073,880 as of June 30, 2026; $ 398,690 as of December 31, 2025. In thousands.
Analysis
Tango's quarter was defined by clinical advancement rather than revenue generation. The Company reported that vopimetostat plus daraxonrasib achieved a 92% objective response rate and a 90% six-month progression-free survival rate in MTAP-deleted, RAS-mutant pancreatic cancer. Tango is using those initial Phase 1/2 results to pursue a registrational plan with regulators and Revolution Medicines and expects to finalize the design of a Phase 3 randomized-controlled trial in front-line pancreatic cancer in 2H 2026.
The income statement reflects the end of the Gilead collaboration revenue stream. Collaboration revenue was $ — for the three months ended June 30, 2026, compared with $ 3,181 for the prior-year period. The Company stated that all remaining deferred revenue from upfront and research option-extension payments under the Gilead collaboration was recognized during the year ended December 31, 2025 after the collaboration agreement was truncated and research activities concluded.
Spending increased as Tango advanced vopimetostat and TNG456. Research and development expense was 37,199 in the quarter compared with 32,807 in the prior-year period, while general and administrative expense was 22,586 compared with 11,341, driven primarily by personnel-related costs including share-based compensation expense. Total operating expenses reached 59,785, and net loss was $ (55,341 ), compared with $ (38,853 ) in the prior-year quarter. The Company noted that portfolio prioritization efforts partially offset the increase in research and development spending.
The balance sheet is positioned to support the stated development plan. Tango held $1.0 billion in cash, cash equivalents and marketable securities as of June 30, 2026, and said this balance is expected to fund its current operating plan. Corporate preparation also advanced with Robert Azelby's appointment as Board Chairman on August 6, 2026 and Fatma Ocak's appointment as Chief Commercialization Officer effective August 17, 2026. Near-term execution points are the ESMO presentation from October 23-27, 2026, Phase 3 design finalization, vopimetostat lung cancer monotherapy data, initial TNG456 data, and initiation of the ERAS-0015 combination study, all identified for 2H 2026.
Management, verbatim
Notably, initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate with encouraging durability in MTAP-deleted, RAS-mutant pancreatic cancer, giving us the confidence to move this combination rapidly into Phase 3 development for patients.
Malte Peters, MD, Chief Executive Officer of Tango
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported financial metrics
- Segment revenue disclosure
- Gross profit and gross margin
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Debt or borrowings
- Share repurchases
- Dividends
- Quantitative revenue guidance
- Quantitative operating-expense guidance
- Quantitative tax-rate guidance
- Previous-release outlook for comparison with actual results
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results plus clinical and corporate updates for Tango’s PRMT5 inhibitor vopimetostat program.
Ticker impact
Tango reported Q2 2026 results and said vopimetostat plus daraxonrasib showed a 92% objective response rate in MTAP-deleted, RAS-mutant pancreatic cancer.
Near-term upside bias on any market reaction to the Phase 1/2 efficacy metrics and cash runway, with volatility into the ESMO data window.
This is a primary 8-K disclosure with specific efficacy outcomes, cash balance, and upcoming catalysts (ESMO presentation and Phase 3 design). However, it is not yet a Phase 3 readout or regulatory decision, limiting certainty.
Market effects
Reinforces investor focus on PRMT5 inhibition and MTAP-deleted, RAS-mutant pancreatic cancer strategies, potentially supporting sentiment for similar precision-oncology programs.
Limited direct regional impact; ESMO timing may drive European biotech sentiment closer to October.
Pancreatic cancer efficacy signals can influence global biotech risk pricing, though impact is company-specific until Phase 3 data.
Counterpoint
High response rate in a Phase 1/2 setting may not translate into Phase 3 efficacy or durability endpoints, so the market may over-discount trial risk.
Key entities
- companyTango Therapeutics, Inc.
Clinical-stage biotech disclosing Q2 2026 financials, vopimetostat plus daraxonrasib Phase 1/2 results, and launch-readiness leadership changes.
- drug_programvopimetostat
MTAP-selective once-daily PRMT5 inhibitor being advanced in combination for pancreatic cancer.
- drug_programdaraxonrasib
RAS(ON) inhibitor used in combination with vopimetostat in the reported pancreatic cancer Phase 1/2 study.
- collaboratorRevolution Medicines
Collaborator whose RAS(ON) inhibitors are used in the combination study referenced in the filing.
- eventESMO Congress 2026
Planned presentation window for the Phase 1/2 combination data (Oct 23-27, 2026).
